Evidence map›Paper›PMID 41822651›Full record

ArticleCureus2026

Rapid Resolution of Pulmonary Embolism and Pacemaker Lead Thrombus With Low-Dose Systemic Thrombolytic Infusion.

Rebecca A Pilkington, Jared W Berger, Shilpa Jasti, Stephen Miller, Ambika Anand

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rebecca A PilkingtonDepartment of Emergency Medicine, Virginia Commonwealth University Medical Center, Richmond, USA.
Jared W BergerDepartment of Emergency Medicine, Virginia Commonwealth University Medical Center, Richmond, USA.
Shilpa JastiDepartment of Emergency Medicine, Virginia Commonwealth University School of Medicine, Richmond, USA.
Stephen MillerDepartment of Emergency Medicine, Virginia Commonwealth University Medical Center, Richmond, USA.
Ambika AnandDepartment of Emergency Medicine, Virginia Commonwealth University Medical Center, Richmond, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pacemaker lead-associated thrombosis is a rare but clinically significant condition that can lead to embolic complications and hemodynamic instability. Management of pacemaker lead-associated thrombi can range from anticoagulation or systemic thrombolysis to catheter-based extraction and surgical removal. In this case, an 80-year-old male patient presented to the Emergency Department (ED) with acute exertional dyspnea and was found to have extensive left lower extremity deep vein thrombosis (DVT), bilateral segmental pulmonary embolism (PE), and a thrombus adhered to the right atrial pacemaker lead. He was treated with low-dose intravenous alteplase infusion as well as heparin in the intensive care unit, leading to rapid thrombus resolution. He was subsequently transitioned to a direct-acting oral anticoagulant (DOAC) and discharged in stable condition. Treatment for pacemaker lead thrombi is not protocolized, given the dependence on various patient-related and situational factors. This case highlights the importance of early recognition and management of pacemaker lead-associated thrombosis and demonstrates a novel treatment approach in the form of low-dose alteplase infusion. Low-dose thrombolytics may be a safer and less invasive treatment modality in hemodynamically stable patients with a high clot burden.

Indexed as

acute pulmonary embolismdeep vein thrombosis (dvt)intravenous thrombolytic therapypacemaker lead thrombusultrasound (u/s)

Identifiers

PMID41822651
PMCPMC12978620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.